Most Read Articles
4 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
2 days ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
17 Aug 2019
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
6 days ago
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.

Buprenorphine–naloxone preferred over extended-release naltrexone to prevent opioid relapse

07 Feb 2019
The opioid epidemic in the US has presented a complicated moral dilemma to doctors when treating potential drug abusers.

Buprenorphine–naloxone is the preferred first-line treatment for opioid use disorder compared with extended-release naltrexone when both options are clinically appropriate and patients require detoxification before initiating extended-release naltrexone, suggests a study.

Buprenorphine–naloxone was preferable to extended-release naltrexone in 97 percent of bootstrap replications at 24 weeks and in 85 percent at 36 weeks on the basis of healthcare sector perspective and a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY).

Moreover, these results were similar with incremental time abstinent from opioids as an outcome and with use of the societal perspective.

Sensitivity analysis revealed that the base-case results were sensitive to the cost of the two treatment and the success of randomized treatment initiation.

The authors conducted a cost-effectiveness analysis alongside a previously reported randomized clinical trial of 570 adults in eight US inpatient or residential treatment programmes. Adults with opioid use disorder underwent a 24-week intervention (buprenorphine–naloxone and extended-release naltrexone) with an additional 12 weeks of observation.

The authors used healthcare sector and societal perspectives. Outcome measures included incremental costs combined with incremental QALYs and incremental time abstinent from opioids.

The study was limited by relatively short follow-up for a chronic condition, substantial missing data, and absence of information on patient out-of-pocket and social service costs.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.
2 days ago
Tofogliflozin is safe and effective for elderly patients with type 2 diabetes mellitus (T2DM), regardless of insulin and oral antidiabetic drugs, reports a new Japan study.
17 Aug 2019
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.
6 days ago
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.